Overcoming Cancer Resistance to Platinum Drugs by Inhibiting Cholesterol Metabolism

Angew Chem Int Ed Engl. 2023 Aug 23:e202309043. doi: 10.1002/anie.202309043. Online ahead of print.ABSTRACTDrug resistance is a serious challenge for platinum anticancer drugs. Platinum complexes may get over the drug resistance via a distinct mechanism of action. Cholesterol is a key factor contributing to the drug resistance. Inhibiting cellular cholesterol synthesis and uptake provides an alternative strategy for cancer treatment. Platinum(IV) complexes FP and DFP with fenofibric acid as axial ligand(s) were designed to combat the drug resistance through regulating cholesterol metabolism besides damaging DNA. In addition to producing reactive oxygen species and active platinum(II) species to damage DNA, FP and DFP inhibited cellular cholesterol accumulation, promoted cholesterol efflux, upregulated peroxisome proliferator-activated receptor alpha (PPARĪ±), induced caspase-1 activation and gasdermin D (GSDMD) cleavage, thus leading to both apoptosis and pyroptosis in cancer cells. The reduction of cholesterol significantly relieved the drug resistance of cancer cells. The double-acting mechanism gave the complexes strong anticancer activity in vitro and vivo, particularly against cisplatin-resistant cancer cells.PMID:37612842 | DOI:10.1002/anie.202309043
Source: Angewandte Chemie - Category: Chemistry Authors: Source Type: research